Replimune Group Inc (NASDAQ:REPL) COO Colin Love Sells 22,500 Shares

Replimune Group Inc (NASDAQ:REPL) COO Colin Love sold 22,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $16.92, for a total transaction of $380,700.00.

Colin Love also recently made the following trade(s):

  • On Thursday, October 31st, Colin Love sold 11,250 shares of Replimune Group stock. The stock was sold at an average price of $17.02, for a total transaction of $191,475.00.
  • On Monday, September 23rd, Colin Love sold 11,250 shares of Replimune Group stock. The stock was sold at an average price of $17.05, for a total transaction of $191,812.50.

Shares of REPL stock traded up $0.07 during mid-day trading on Friday, reaching $16.92. The stock had a trading volume of 185,900 shares, compared to its average volume of 58,871. The stock’s 50-day moving average price is $14.57 and its two-hundred day moving average price is $13.43. The firm has a market capitalization of $538.96 million, a PE ratio of -12.72 and a beta of 3.30. Replimune Group Inc has a 52-week low of $8.88 and a 52-week high of $18.25.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, August 14th. The company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.02. Equities analysts forecast that Replimune Group Inc will post -1.52 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of REPL. Emerald Mutual Fund Advisers Trust increased its position in Replimune Group by 0.5% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 711,770 shares of the company’s stock valued at $10,435,000 after purchasing an additional 3,650 shares during the period. Wells Fargo & Company MN lifted its position in Replimune Group by 211.3% during the second quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock valued at $338,000 after acquiring an additional 15,672 shares during the last quarter. Northern Trust Corp lifted its position in Replimune Group by 1.2% during the second quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock valued at $1,817,000 after acquiring an additional 1,437 shares during the last quarter. Foresite Capital Management III LLC increased its stake in Replimune Group by 4.0% during the 2nd quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock valued at $11,430,000 after purchasing an additional 30,002 shares in the last quarter. Finally, BlackRock Inc. increased its stake in Replimune Group by 8.2% during the 2nd quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock valued at $14,883,000 after purchasing an additional 76,540 shares in the last quarter. 60.74% of the stock is currently owned by institutional investors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Replimune Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 26th. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Replimune Group in a report on Thursday, October 24th. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Replimune Group in a report on Monday, September 30th. ValuEngine raised shares of Replimune Group from a “sell” rating to a “hold” rating in a report on Monday, November 4th. Finally, Roth Capital initiated coverage on shares of Replimune Group in a report on Wednesday, September 4th. They set a “buy” rating and a $20.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $23.50.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Read More: Market Capitalization – What it Means for Investors

Insider Buying and Selling by Quarter for Replimune Group (NASDAQ:REPL)

Leave a Reply

Your email address will not be published. Required fields are marked *

*